文献速递白血病MDS 与骨髓增殖性肿瘤

JAK2 V617F 阳性急性髓系白血病(AML):原发 AML 与由潜在骨髓增殖性肿瘤转化而来的继发性 AML 的比较。骨髓病理学组研究

JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
PubMed 文献 · Br J Haematol · 2018-05-16

研究纳入45例JAK2 V617F突变AML患者,其中原发AML 15例、继发于MPN的AML 30例。继发性AML更常见脾肿大、MPN样巨核细胞及诊断时较高的JAK2 V617F VAF;原发AML中TET2突变仅见于该组,DNA甲基化相关基因突变更常见。原发AML诱导化疗后骨髓组织学未见隐匿MPN形态学证据,而继发性AML多数存在。

要点

  • JAK2 V617F突变AML中,继发于MPN者较原发AML更常出现脾肿大和MPN样巨核细胞。
  • 原发AML中TET2突变仅见于该组,DNA甲基化相关基因突变更常见。
  • 继发性AML较原发AML更常见复杂核型,原发AML更常见正常核型。

核心结论

  • 本最大样本的JAK2 V617F突变AML研究提示,原发AML与继发于MPN的AML是两种不同的疾病实体。

研究设计与样本

  • 研究识别出45例JAK2 V617F突变AML患者,其中15例为原发AML(AML-DN),30例为继发于MPN的AML(AML-MPN)。

主要发现

  • AML-MPN组较AML-DN组更常见脾肿大(P=0.02)。
  • AML-MPN组较AML-DN组更常见MPN样巨核细胞,且诊断时平均JAK2 V617F VAF更高(P=0.04)。
  • TET2突变仅见于AML-DN组。
  • AML-DN组较AML-MPN组更常见DNA甲基化相关基因突变(P<0.01)。
  • AML-MPN组较AML-DN组更常见复杂核型(P<0.01),AML-DN组较AML-MPN组更常见正常核型(P=0.02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The JAK2 V617F mutation is characteristic of most Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) and occurs rarely in de novo acute myeloid leukaemia (AML). We sought to characterize AMLs that harbour this mutation and distinguish those that arise de novo (AML-DN) from those that reflect transformation of an underlying MPN (AML-MPN). Forty-five patients with JAK2 V617F-mutated AML were identified; 15 were AML-DN and 30 were AML-MPN. AML-MPN cases were more likely to have splenomegaly (P = 0·02), MPN-like megakaryocytes and higher mean JAK2 V617F VAF at diagnosis (P = 0·04). Mutations involving TET2 were exclusively identified in AML-DN patients. Mutations of genes affecting DNA methylation were more common in AML-DN (P < 0·01). A complex karyotype was more frequent in AML-MPN cases than in AML-DN (P < 0·01), with AML-DN more likely to display a normal karyotype (P = 0·02). Bone marrow histology after recovery from induction chemotherapy in AML-DN cases revealed no morphological evidence of any previously occult MPNs, while this was evident in most of the AML-MPN specimens (P < 0·01). These findings in this largest study of JAK2 V617F-mutated AMLs indicate that AML-DN is distinct from AML-MPN.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Aynardi J, Manur R, Hess PR, et al. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. Br J Haematol. 2018. PMID: 29767839. doi:10.1111/bjh.15276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。